Found: 7
Select item for more details and to access through your institution.
Outcomes of relapsed/refractory diffuse large B‐cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line—A population‐based study of 736 patients.
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 2, p. 267, doi. 10.1111/bjh.18197
- By:
- Publication type:
- Article
Survival of very elderly patients with diffuse large B‐cell lymphoma according to treatment intensity in the immunochemotherapy era: a Swedish Lymphoma Register study.
- Published in:
- British Journal of Haematology, 2021, v. 192, n. 1, p. 75, doi. 10.1111/bjh.16737
- By:
- Publication type:
- Article
Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden.
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41408-020-00403-1
- By:
- Publication type:
- Article
Patient trajectories after diagnosis of diffuse large B-cell lymphoma-a multistate modelling approach to estimate the chance of lasting remission.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Outcome and determinants of failure to complete primary R‐CHOP treatment for reasons other than non‐response among patients with diffuse large B‐cell lymphoma.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 7, p. 740, doi. 10.1002/ajh.25789
- By:
- Publication type:
- Article
ROR1 is Expressed in Diffuse Large B-Cell Lymphoma (DLBCL) and a Small Molecule Inhibitor of ROR1 (KAN0441571C) Induced Apoptosis of Lymphoma Cells.
- Published in:
- Biomedicines, 2020, v. 8, n. 6, p. 170, doi. 10.3390/biomedicines8060170
- By:
- Publication type:
- Article
Excellent survival after R‐Hyper‐CVAD in hospitalized patients with high‐risk large B‐cell lymphoma: The Karolinska experience.
- Published in:
- EJHaem, 2021, v. 2, n. 4, p. 774, doi. 10.1002/jha2.296
- By:
- Publication type:
- Article